Recent News

• 04.03.2025 - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
• 03.31.2025 - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
• 12.20.2024 - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
• 12.10.2024 - Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
• 11.21.2024 - Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
• 09.16.2024 - Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
• 09.04.2024 - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
• 08.14.2024 - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
• 08.13.2024 - Canaccord Genuity 44th Annual Growth Conference

Recent Filings

• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.20.2024 - EX-99.1 EX-99.1
• 12.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2024 - EX-99.1 EX-99.1
• 11.14.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.01.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.15.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership